| Name | Title | Contact Details |
|---|
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.
Gensource-Rx is a Carlstadt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hoechst AG is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
Cynapsus Therapeutics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.